TY - JOUR
T1 - Identification of Structural Features of Heparin Required for Inhibition of Herpes Simplex Virus Type 1 Binding
AU - Herold, Betsy C.
AU - Gerber, Susan Ilene
AU - Polonsky, Tamar
AU - Belval, Brian J.
AU - Shaklee, Patrick N.
AU - Holme, Kevin
PY - 1995/2/1
Y1 - 1995/2/1
N2 - Binding of HSV-1 to cells is mediated by interactions of virion glycoproteins gC and/or gB with heparan sulfate (HS) glycosaminoglycans on cell surface proteoglycans. HS and the related glycosaminoglycan, heparin, comprise a family of heterogeneous carbohydrates composed of long, unbranched polysaccharides modified, for example, by sulfations and acetylations. To define the specific features of HS important for viral binding, we took advantage of the structural similarities between heparin and cell surface HS and compared the ability of chemically modified heparin compounds to inhibit the binding of viral particles to the cell surface and subsequent plaque formation. Because binding presumably involves multiple, complex interactions between both known heparin-binding glycoproteins, gC and gB, and cell surface HS, we compared the effects of modified heparin compounds on the binding and subsequent plaque formation of wild-type and gC-negative strains of HSV-1 and, in select cases, the binding of gB-negative virus to cells. We identified specific structural features of heparin essential for the inhibition of viral binding. For example, both N-sulfation and 6-O-sulfation must be important determinants since desulfation of heparin at these sites abolished or decreased the antiviral activity of heparin. Moreover, we found that the antiviral activity of heparin was independent of its anticoagulant activity. Carboxyl-reduced and 2-,3-O-desulfated heparin selectively inhibited binding of gC-positive viruses (wild-type or a gB-negative strain) to cells, but had little or no inhibitory effect on binding and subsequent plaque formation for a gC-deletion virus. These results suggest that gC and gB interact with different structural features of HS.
AB - Binding of HSV-1 to cells is mediated by interactions of virion glycoproteins gC and/or gB with heparan sulfate (HS) glycosaminoglycans on cell surface proteoglycans. HS and the related glycosaminoglycan, heparin, comprise a family of heterogeneous carbohydrates composed of long, unbranched polysaccharides modified, for example, by sulfations and acetylations. To define the specific features of HS important for viral binding, we took advantage of the structural similarities between heparin and cell surface HS and compared the ability of chemically modified heparin compounds to inhibit the binding of viral particles to the cell surface and subsequent plaque formation. Because binding presumably involves multiple, complex interactions between both known heparin-binding glycoproteins, gC and gB, and cell surface HS, we compared the effects of modified heparin compounds on the binding and subsequent plaque formation of wild-type and gC-negative strains of HSV-1 and, in select cases, the binding of gB-negative virus to cells. We identified specific structural features of heparin essential for the inhibition of viral binding. For example, both N-sulfation and 6-O-sulfation must be important determinants since desulfation of heparin at these sites abolished or decreased the antiviral activity of heparin. Moreover, we found that the antiviral activity of heparin was independent of its anticoagulant activity. Carboxyl-reduced and 2-,3-O-desulfated heparin selectively inhibited binding of gC-positive viruses (wild-type or a gB-negative strain) to cells, but had little or no inhibitory effect on binding and subsequent plaque formation for a gC-deletion virus. These results suggest that gC and gB interact with different structural features of HS.
UR - http://www.scopus.com/inward/record.url?scp=0028876742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028876742&partnerID=8YFLogxK
U2 - 10.1006/viro.1995.1034
DO - 10.1006/viro.1995.1034
M3 - Article
C2 - 7856085
AN - SCOPUS:0028876742
SN - 0042-6822
VL - 206
SP - 1108
EP - 1116
JO - Virology
JF - Virology
IS - 2
M1 - 71034
ER -